The same study showed that there was no statistically significant association between osteopontin immunostaining and tumour stage (FIGO stage) and tumour size, but there was evidence of better survival rates for patients found to have increased osteopontin immunostaining [1]. This evidence concerns the gene SPP1 and neoplasm.